Hosted on MSN

Pfizer's mRNA flu shot outperforms standard flu vaccine in late-stage trial

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...
Benzinga.com

Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains

A Phase 3 study funded by Pfizer Inc. (NYSE: PFE) suggests that a nucleoside-modified messenger RNA influenza vaccine could offer stronger protection than traditional flu shots, marking a potential ...
UPI

mRNA flu shot shows better results than traditional vaccine in trial

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The results, published Nov. 19 in The New England Journal of Medicine, suggest that ...
STAT

Pfizer’s mRNA-based flu shot offered better protection than standard vaccine

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...